Autologous Tumor-infiltrating Lymphocyte（Yishou Technology）

自体肿瘤浸润淋巴细胞（翊寿科技）

Report date: 2023/12/18 17:53:40

Base Information

Drug NameAutologous Tumor-infiltrating Lymphocyte（Yishou Technology）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionLymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Yishou Technology Co LtdHainan Yishou Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHainan Yishou Technology Co LtdWuhan Yishou Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A